Browse PAK3

Summary
SymbolPAK3
Namep21 protein (Cdc42/Rac)-activated kinase 3
Aliases hPAK3; bPAK; MRX30; MRX47; mental retardation, X-linked 47; p21 (CDKN1A)-activated kinase 3; OPHN3; PAK-3bet ......
Chromosomal LocationXq22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF00786 P21-Rho-binding domain
PF00069 Protein kinase domain
Function

Serine/threonine protein kinase that plays a role in a variety of different signaling pathways including cytoskeleton regulation, cell migration, or cell cycle regulation. Plays a role in dendrite spine morphogenesis as well as synapse formation and plasticity. Acts as downstream effector of the small GTPases CDC42 and RAC1. Activation by the binding of active CDC42 and RAC1 results in a conformational change and a subsequent autophosphorylation on several serine and/or threonine residues. Phosphorylates MAPK4 and MAPK6 and activates the downstream target MAPKAPK5, a regulator of F-actin polymerization and cell migration. Additionally, phosphorylates TNNI3/troponin I to modulate calcium sensitivity and relaxation kinetics of thin myofilaments. May also be involved in early neuronal development.

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0001667 ameboidal-type cell migration
GO:0002218 activation of innate immune response
GO:0002220 innate immune response activating cell surface receptor signaling pathway
GO:0002223 stimulatory C-type lectin receptor signaling pathway
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0007015 actin filament organization
GO:0007159 leukocyte cell-cell adhesion
GO:0007409 axonogenesis
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0010720 positive regulation of cell development
GO:0010761 fibroblast migration
GO:0010762 regulation of fibroblast migration
GO:0010763 positive regulation of fibroblast migration
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010975 regulation of neuron projection development
GO:0010976 positive regulation of neuron projection development
GO:0016358 dendrite development
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0022604 regulation of cell morphogenesis
GO:0030041 actin filament polymerization
GO:0030335 positive regulation of cell migration
GO:0030832 regulation of actin filament length
GO:0030833 regulation of actin filament polymerization
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0031346 positive regulation of cell projection organization
GO:0031349 positive regulation of defense response
GO:0032147 activation of protein kinase activity
GO:0032271 regulation of protein polymerization
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0033674 positive regulation of kinase activity
GO:0040017 positive regulation of locomotion
GO:0042110 T cell activation
GO:0043254 regulation of protein complex assembly
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043523 regulation of neuron apoptotic process
GO:0043525 positive regulation of neuron apoptotic process
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045666 positive regulation of neuron differentiation
GO:0045785 positive regulation of cell adhesion
GO:0045860 positive regulation of protein kinase activity
GO:0048013 ephrin receptor signaling pathway
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048813 dendrite morphogenesis
GO:0048814 regulation of dendrite morphogenesis
GO:0050769 positive regulation of neurogenesis
GO:0050773 regulation of dendrite development
GO:0050775 positive regulation of dendrite morphogenesis
GO:0050808 synapse organization
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051258 protein polymerization
GO:0051272 positive regulation of cellular component movement
GO:0051402 neuron apoptotic process
GO:0051493 regulation of cytoskeleton organization
GO:0051962 positive regulation of nervous system development
GO:0060996 dendritic spine development
GO:0060997 dendritic spine morphogenesis
GO:0060998 regulation of dendritic spine development
GO:0060999 positive regulation of dendritic spine development
GO:0061001 regulation of dendritic spine morphogenesis
GO:0061003 positive regulation of dendritic spine morphogenesis
GO:0061564 axon development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070997 neuron death
GO:0071407 cellular response to organic cyclic compound
GO:0071593 lymphocyte aggregation
GO:0071897 DNA biosynthetic process
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0090066 regulation of anatomical structure size
GO:0097061 dendritic spine organization
GO:1900006 positive regulation of dendrite development
GO:1901214 regulation of neuron death
GO:1901216 positive regulation of neuron death
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:2000147 positive regulation of cell motility
GO:2000278 regulation of DNA biosynthetic process
GO:2000573 positive regulation of DNA biosynthetic process
Molecular Function GO:0004674 protein serine/threonine kinase activity
GO:0004702 receptor signaling protein serine/threonine kinase activity
GO:0004708 MAP kinase kinase activity
GO:0004712 protein serine/threonine/tyrosine kinase activity
GO:0005057 receptor signaling protein activity
GO:0017016 Ras GTPase binding
GO:0017048 Rho GTPase binding
GO:0017124 SH3 domain binding
GO:0031267 small GTPase binding
GO:0051020 GTPase binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04012 ErbB signaling pathway
hsa04014 Ras signaling pathway
hsa04360 Axon guidance
hsa04510 Focal adhesion
hsa04660 T cell receptor signaling pathway
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-428540: Activation of Rac
R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5621575: CD209 (DC-SIGN) signaling
R-HSA-389356: CD28 co-stimulation
R-HSA-389359: CD28 dependent Vav1 pathway
R-HSA-388841: Costimulation by the CD28 family
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928664: Ephrin signaling
R-HSA-202433: Generation of second messenger molecules
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-5683057: MAPK family signaling cascades
R-HSA-5687128: MAPK6/MAPK4 signaling
R-HSA-195258: RHO GTPase Effectors
R-HSA-5627123: RHO GTPases activate PAKs
R-HSA-399954: Sema3A PAK dependent Axon repulsion
R-HSA-373755: Semaphorin interactions
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
R-HSA-376176: Signaling by Robo receptor
R-HSA-194138: Signaling by VEGF
R-HSA-202403: TCR signaling
R-HSA-4420097: VEGFA-VEGFR2 Pathway
R-HSA-5218920: VEGFR2 mediated vascular permeability
Summary
SymbolPAK3
Namep21 protein (Cdc42/Rac)-activated kinase 3
Aliases hPAK3; bPAK; MRX30; MRX47; mental retardation, X-linked 47; p21 (CDKN1A)-activated kinase 3; OPHN3; PAK-3bet ......
Chromosomal LocationXq22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PAK3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolPAK3
Namep21 protein (Cdc42/Rac)-activated kinase 3
Aliases hPAK3; bPAK; MRX30; MRX47; mental retardation, X-linked 47; p21 (CDKN1A)-activated kinase 3; OPHN3; PAK-3bet ......
Chromosomal LocationXq22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PAK3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolPAK3
Namep21 protein (Cdc42/Rac)-activated kinase 3
Aliases hPAK3; bPAK; MRX30; MRX47; mental retardation, X-linked 47; p21 (CDKN1A)-activated kinase 3; OPHN3; PAK-3bet ......
Chromosomal LocationXq22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PAK3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9070.0287
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4980.661
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.4250.289
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3520.586
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5780.561
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.160.883
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3070.492
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7430.222
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2770.272
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PAK3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.111.8-4.71
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031066.7-56.70.108
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPAK3
Namep21 protein (Cdc42/Rac)-activated kinase 3
Aliases hPAK3; bPAK; MRX30; MRX47; mental retardation, X-linked 47; p21 (CDKN1A)-activated kinase 3; OPHN3; PAK-3bet ......
Chromosomal LocationXq22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PAK3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPAK3
Namep21 protein (Cdc42/Rac)-activated kinase 3
Aliases hPAK3; bPAK; MRX30; MRX47; mental retardation, X-linked 47; p21 (CDKN1A)-activated kinase 3; OPHN3; PAK-3bet ......
Chromosomal LocationXq22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PAK3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PAK3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPAK3
Namep21 protein (Cdc42/Rac)-activated kinase 3
Aliases hPAK3; bPAK; MRX30; MRX47; mental retardation, X-linked 47; p21 (CDKN1A)-activated kinase 3; OPHN3; PAK-3bet ......
Chromosomal LocationXq22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PAK3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPAK3
Namep21 protein (Cdc42/Rac)-activated kinase 3
Aliases hPAK3; bPAK; MRX30; MRX47; mental retardation, X-linked 47; p21 (CDKN1A)-activated kinase 3; OPHN3; PAK-3bet ......
Chromosomal LocationXq22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PAK3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPAK3
Namep21 protein (Cdc42/Rac)-activated kinase 3
Aliases hPAK3; bPAK; MRX30; MRX47; mental retardation, X-linked 47; p21 (CDKN1A)-activated kinase 3; OPHN3; PAK-3bet ......
Chromosomal LocationXq22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PAK3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPAK3
Namep21 protein (Cdc42/Rac)-activated kinase 3
Aliases hPAK3; bPAK; MRX30; MRX47; mental retardation, X-linked 47; p21 (CDKN1A)-activated kinase 3; OPHN3; PAK-3bet ......
Chromosomal LocationXq22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PAK3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.